MX2024013454A - Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion - Google Patents

Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion

Info

Publication number
MX2024013454A
MX2024013454A MX2024013454A MX2024013454A MX2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A
Authority
MX
Mexico
Prior art keywords
cohn
ultrafiltration
preparing
methods
blood plasma
Prior art date
Application number
MX2024013454A
Other languages
English (en)
Spanish (es)
Inventor
Ivano Martelli
Oliver Mieselberger
Francesca Micheli
Alexander Zaydenberg
Jarrod Hanson
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2024013454A publication Critical patent/MX2024013454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/027—Nanofiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/58—Multistep processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D65/00—Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
    • B01D65/02—Membrane cleaning or sterilisation ; Membrane regeneration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2321/00—Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/16—Use of chemical agents
    • B01D2321/162—Use of acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Water Supply & Treatment (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
MX2024013454A 2022-05-02 2024-10-31 Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion MX2024013454A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263337439P 2022-05-02 2022-05-02
US202363498470P 2023-04-26 2023-04-26
PCT/US2023/066457 WO2023215722A1 (en) 2022-05-02 2023-05-01 Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Publications (1)

Publication Number Publication Date
MX2024013454A true MX2024013454A (es) 2024-12-06

Family

ID=86646677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013454A MX2024013454A (es) 2022-05-02 2024-10-31 Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion

Country Status (9)

Country Link
US (1) US20250281530A1 (enExample)
EP (1) EP4518875A1 (enExample)
JP (1) JP2025514479A (enExample)
KR (1) KR20250004876A (enExample)
CN (1) CN119300842A (enExample)
AU (1) AU2023264066A1 (enExample)
MX (1) MX2024013454A (enExample)
TW (1) TW202400621A (enExample)
WO (1) WO2023215722A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) 1942-02-09 1945-12-04 Research Corp Protein product and process
DE2902158A1 (de) * 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
WO2011011753A1 (en) * 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
BR112013001753A2 (pt) * 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
MY165164A (en) * 2011-08-26 2018-02-28 Baxalta Inc Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP4240757A2 (en) * 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Also Published As

Publication number Publication date
TW202400621A (zh) 2024-01-01
AU2023264066A1 (en) 2024-10-31
WO2023215722A1 (en) 2023-11-09
KR20250004876A (ko) 2025-01-08
JP2025514479A (ja) 2025-05-02
CN119300842A (zh) 2025-01-10
US20250281530A1 (en) 2025-09-11
EP4518875A1 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
CO2023001489A2 (es) Proceso de fraccionamiento de plasma usando plasma humano secado por atomización
CL2024002249A1 (es) Muteína de il-21; conjugado; método de producción; composición farmacéutica; y su uso.
AR113011A1 (es) Vesículas extracelulares bacterianas
AR083561A1 (es) Preparacion de una construccion antigenica
AR050641A1 (es) Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
CR20210444A (es) Composiciones y métodos para tratar distrofia cristalina de bietti
ATE415817T1 (de) Agrochemische formulierungen
CO6390111A2 (es) Productos sanguíneos deshidratados por aspersión y métodos para elaborar los mismos
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
RU2012134974A (ru) Стабилизированное соединение гормона роста
CL2024002972A1 (es) Uso de un antagonista del vegf para tratar trastornos oculares angiogénicos.
RU2019126232A (ru) Пептиды и способы для лечения диабета
UY40209A (es) Proceso para preparar (15¿,16¿,17¿)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol monohidrato (estetrol monohidrato)
BR112021024043A2 (pt) Implante mamário biológico
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途
MX2024004003A (es) Proceso para preparar monohidrato de (15alfa,16alfa,17beta)-estra- 1,3,5(10)-trien-3,15,16,17-tetrol (estetrol).
CO2026000249A2 (es) Proteínas de fusión de citocinas únicas y múltiples y usos de estas
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
WO2023081194A3 (en) Methods for treating alzheimer's disease
MX2020010018A (es) Metodo para producir una composicion inmunogenica.
CL2018001704A1 (es) Productos lácteos saborizados
CY1115326T1 (el) Φυτικη συνθεση για τη θεραπεια ή την προληψη ιογενων νοσων του αιματος, που προκαλουνται απο τον ιο της ανθρωπινης ανοσοανεπαρκειας (hiv) ή την ηπατιτιδα c